Sernova Opens the Market

TORONTO , June 2, 2022 /CNW/ - Dr. Philip Toleikis , President and Chief Executive Officer, Sernova Corp. (TSXV: SVA) and his team joined Tanya Rowntree , Global Head of Client Success, Toronto Stock Exchange (TSX), to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market.

Sernova Corp is a clinical-stage biotechnology company developing regenerative therapeutic technologies to deliver a 'functional cure' for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders like hemophilia A. An ongoing Phase I/II study at the University of Chicago has treated the first 6 patients with type 1 diabetes using its implantable Cell Pouch™ therapy device. The longest patient has now achieved 25 months with no insulin injections needed and a second patient has been insulin independent for over seven months. Sernova and Evotec recently entered into an option and licensing partnership to develop an implantable off-the-shelf iPSC-based beta cell replacement therapy to provide Sernova an unlimited supply of insulin-producing cells for use with its Cell Pouch System to treat potentially millions of patients with insulin-dependent diabetes.

SOURCE Toronto Stock Exchange

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/02/c5699.html